Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Human prostate stem cell antigen and HSP70 fusion protein vaccine inhibits prostate stem cell antigen-expressing tumor growth in mice.

Dong L, Zhang X, Ren J, Wu S, Yu T, Hou L, Fu L, Yi S, Yu C.

Cancer Biother Radiopharm. 2013 Jun;28(5):391-7. doi: 10.1089/cbr.2012.1357. Epub 2013 May 23.

PMID:
23701419
2.
3.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311
5.

A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer.

Zhang KQ, Yang F, Ye J, Jiang M, Liu Y, Jin FS, Wu YZ.

Urology. 2012 Jun;79(6):1410.e7-13. doi: 10.1016/j.urology.2012.02.011. Epub 2012 Apr 17.

PMID:
22513035
6.

Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo.

Ma JH, Sui YF, Ye J, Huang YY, Li ZS, Chen GS, Qu P, Song HP, Zhang XM.

Cancer Immunol Immunother. 2005 Sep;54(9):907-14. Epub 2005 Mar 9.

PMID:
15756604
7.

Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice.

Huo W, Ye J, Liu R, Chen J, Li Q.

Vaccine. 2010 Aug 31;28(38):6333-7. doi: 10.1016/j.vaccine.2010.06.093. Epub 2010 Jul 14.

PMID:
20637304
8.

Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells.

Zhao Z, Ma W, Zeng G, Qi D, Ou L, Liang Y.

Urol Oncol. 2013 Apr;31(3):343-51. doi: 10.1016/j.urolonc.2011.02.004. Epub 2011 Mar 23.

PMID:
21429770
9.

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.

Hillerdal V, Ramachandran M, Leja J, Essand M.

BMC Cancer. 2014 Jan 18;14:30. doi: 10.1186/1471-2407-14-30.

10.

RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.

Zhao Z, He J, Kang R, Zhao S, Liu L, Li F.

Prostate. 2016 Feb;76(2):184-98. doi: 10.1002/pros.23110. Epub 2015 Oct 19.

PMID:
26477693
11.

Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.

Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM.

Cancer Res. 2008 Feb 1;68(3):861-9. doi: 10.1158/0008-5472.CAN-07-0445.

12.

Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.

Xiao L, Joo KI, Lim M, Wang P.

PLoS One. 2012;7(11):e48866. doi: 10.1371/journal.pone.0048866. Epub 2012 Nov 6.

13.

A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis.

Qu P, Ma JH, Zhang XM, Huang XJ, Yang XW, Yan-Fang S.

Indian J Exp Biol. 2010 May;48(5):436-43.

PMID:
20795360
14.

Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth.

Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC.

Mol Ther. 2009 Jun;17(6):1101-8. doi: 10.1038/mt.2009.66. Epub 2009 Mar 31.

15.

Fusion of Hsp70 to Mage-a1 enhances the potency of vaccine-specific immune responses.

Jiang J, Xie D, Zhang W, Xiao G, Wen J.

J Transl Med. 2013 Dec 5;11:300. doi: 10.1186/1479-5876-11-300.

16.

Heat shock protein 70 / MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo.

Ye J, Chen GS, Song HP, Li ZS, Huang YY, Qu P, Sun YJ, Zhang XM, Sui YF.

Cancer Immunol Immunother. 2004 Sep;53(9):825-34. Epub 2004 Apr 30.

PMID:
15127237
17.

Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter.

Watabe T, Lin M, Ide H, Donjacour AA, Cunha GR, Witte ON, Reiter RE.

Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):401-6. Epub 2001 Dec 18.

18.

Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.

Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG.

Prostate. 2002 Nov 1;53(3):183-91.

19.

Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.

Dannull J, Diener PA, Prikler L, F├╝rstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M.

Cancer Res. 2000 Oct 1;60(19):5522-8.

20.

Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.

Fu Q, Wu Y, Yan F, Wang N, Wang W, Cao X, Wang Y, Wan T.

Cell Mol Immunol. 2011 Sep;8(5):424-32. doi: 10.1038/cmi.2011.21. Epub 2011 Jul 25.

Supplemental Content

Support Center